Logo image of CMPS

COMPASS PATHWAYS PLC (CMPS) Stock Fundamental Analysis

NASDAQ:CMPS - Nasdaq - US20451W1018 - ADR - Currency: USD

4.36  +0.18 (+4.31%)

After market: 4.37 +0.01 (+0.23%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CMPS. CMPS was compared to 561 industry peers in the Biotechnology industry. Both the profitability and financial health of CMPS have multiple concerns. CMPS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CMPS had negative earnings in the past year.
In the past year CMPS has reported a negative cash flow from operations.
CMPS had negative earnings in each of the past 5 years.
CMPS had a negative operating cash flow in each of the past 5 years.
CMPS Yearly Net Income VS EBIT VS OCF VS FCFCMPS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

CMPS has a Return On Assets (-43.18%) which is comparable to the rest of the industry.
CMPS has a Return On Equity (-70.50%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -43.18%
ROE -70.5%
ROIC N/A
ROA(3y)-53.97%
ROA(5y)-43.08%
ROE(3y)-67.74%
ROE(5y)-51.83%
ROIC(3y)N/A
ROIC(5y)N/A
CMPS Yearly ROA, ROE, ROICCMPS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CMPS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMPS Yearly Profit, Operating, Gross MarginsCMPS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, CMPS has more shares outstanding
CMPS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CMPS is higher compared to a year ago.
CMPS Yearly Shares OutstandingCMPS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CMPS Yearly Total Debt VS Total AssetsCMPS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

CMPS has an Altman-Z score of -1.46. This is a bad value and indicates that CMPS is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.46, CMPS is in line with its industry, outperforming 58.11% of the companies in the same industry.
CMPS has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
CMPS has a Debt to Equity ratio of 0.11. This is in the lower half of the industry: CMPS underperforms 66.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -1.46
ROIC/WACCN/A
WACCN/A
CMPS Yearly LT Debt VS Equity VS FCFCMPS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 10.18 indicates that CMPS has no problem at all paying its short term obligations.
CMPS has a Current ratio of 10.18. This is in the better half of the industry: CMPS outperforms 79.86% of its industry peers.
A Quick Ratio of 10.18 indicates that CMPS has no problem at all paying its short term obligations.
CMPS has a Quick ratio of 10.18. This is in the better half of the industry: CMPS outperforms 79.86% of its industry peers.
Industry RankSector Rank
Current Ratio 10.18
Quick Ratio 10.18
CMPS Yearly Current Assets VS Current LiabilitesCMPS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 27.00% over the past year.
EPS 1Y (TTM)27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CMPS will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.62% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y23.18%
EPS Next 2Y15.53%
EPS Next 3Y11.73%
EPS Next 5Y9.62%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CMPS Yearly Revenue VS EstimatesCMPS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 500M 1B
CMPS Yearly EPS VS EstimatesCMPS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CMPS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CMPS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMPS Price Earnings VS Forward Price EarningsCMPS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMPS Per share dataCMPS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.53%
EPS Next 3Y11.73%

More info and screens

0

5. Dividend

5.1 Amount

CMPS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COMPASS PATHWAYS PLC

NASDAQ:CMPS (5/23/2025, 9:23:42 PM)

After market: 4.37 +0.01 (+0.23%)

4.36

+0.18 (+4.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)07-30 2025-07-30
Inst Owners43.32%
Inst Owner Change72.6%
Ins Owners1.84%
Ins Owner Change1.65%
Market Cap404.82M
Analysts84.71
Price Target17 (289.91%)
Short Float %6.23%
Short Ratio5.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)53.23%
Min EPS beat(2)2.27%
Max EPS beat(2)104.19%
EPS beat(4)3
Avg EPS beat(4)26.38%
Min EPS beat(4)-4.82%
Max EPS beat(4)104.19%
EPS beat(8)4
Avg EPS beat(8)-0.22%
EPS beat(12)7
Avg EPS beat(12)4.21%
EPS beat(16)9
Avg EPS beat(16)3.51%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20.21%
EPS NQ rev (1m)3.55%
EPS NQ rev (3m)9.2%
EPS NY rev (1m)3.33%
EPS NY rev (3m)9.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.07
P/tB 2.07
EV/EBITDA N/A
EPS(TTM)-1.73
EYN/A
EPS(NY)-1.53
Fwd EYN/A
FCF(TTM)-1.55
FCFYN/A
OCF(TTM)-1.55
OCFYN/A
SpS0
BVpS2.11
TBVpS2.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.18%
ROE -70.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.97%
ROA(5y)-43.08%
ROE(3y)-67.74%
ROE(5y)-51.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.18
Quick Ratio 10.18
Altman-Z -1.46
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)69.7%
Cap/Depr(5y)102.12%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.64%
EPS Next Y23.18%
EPS Next 2Y15.53%
EPS Next 3Y11.73%
EPS Next 5Y9.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-41.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.21%
EBIT Next 3Y3.61%
EBIT Next 5Y12.02%
FCF growth 1Y-30.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.86%
OCF growth 3YN/A
OCF growth 5YN/A